North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market
No. of Pages: 76 | Report Code: TIPRE00025060 | Category: Life Sciences
No. of Pages: 76 | Report Code: TIPRE00025060 | Category: Life Sciences
North America market has been segmented into the US, Canada, and Mexico. The US dominated the North America market in 2020. The market's growth is primarily attributed to the increasing prevalence of conditions such as immunodeficiency syndromes and pancreatic exocrine insufficiency amongst others. Growing prevalence of risk factors associated with the SIBO are also expected to drive the prevalence of the condition, which will eventually offer favorable environment for growth of US small intestinal bacterial overgrowth diagnostics market by 2027. For instance, according to a study published by group of researchers at Northwell Health System, Division of Gastroenterology, New York in 2017, obesity is one of the prominent causes and risk factors to drive the bacterial overgrowth in small intestine. Small intestinal bacterial overgrowth (SIBO) has been incorporated with anatomical and motility-related abnormalities. Mainly, obesity has been proposed to change small bowel motility, leading to SIBO. As a result, SIBO was more frequent amongst obese patients vs. non-obese patients (88.9% vs. 42.9%). Obese vs. non-obese patients presented notable differences in microbiome diversity in rectal samples. Obesity was connected with increased odds of developing SIBO. Therefore, rising prevalence of obesity will ultimately offer a lucrative opportunity for growth of the market. Growing prevalence of IBS and SIBO and increasing advantages of breath test are the major factor driving the growth of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market.
In case of COVID-19, North America is highly affected specially the US. Industrial sectors in the countries such as the US and Canada has experienced disruption in various industries, including healthcare. However, the need for diagnosis and treatment for the COVID positive patients has carried on business cycles in the medical sector. In addition, the rising demand for personal protective equipment has tried to stabilize the business cycle for the healthcare industry. According to an article issued by Harvard Medical School, infectious viral particles can live in the air for three hours. As a result, it can cause patient scheduling obstructions and put others at risk for contracting the virus. For healthcare providers demanding to test for GI-related problems offered by patients, a substitute for in-office breath testing must be granted due to the potential spread of COVID-19 through aerosolization. Unfortunately, the possible aerosolization spread of COVID-19 makes breath testing in-office comparatively unsafe and has been in a bit of a dilemma in the clinic during this pandemic. The small intestinal bacterial overgrowth diagnostics market also witnessed major decline due to lowered number of diagnostic procedures. Substantial focus on management of COVID had direct impact on diagnostics of abdominal conditions such as irritable bowel syndrome, SIBO, and lactose intolerance. In addition, patients showed reluctance for breath and blood tests due to fear of COVID infection. These factors consequently led to adverse impact on North America small intestinal bacterial overgrowth market during the pandemic period. However, the market is expected to witness considerable growth post-pandemic. Certain factors such as rise in prevalence of SIBO and IBS are estimated to show positive impact on market growth.
Strategic insights for the North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 53,452.06 thousand |
| Market Size by 2028 | US$ 73,794.03 thousand |
| Global CAGR (2021 - 2028) | 4.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Diagnosis
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America small intestinal bacterial overgrowth (SIBO) diagnostics market is expected to grow from US$ 53,452.06 thousand in 2021 to US$ 73,794.03 thousand by 2028; it is estimated to grow at a CAGR of 4.7% from 2021 to 2028. There has been a constant development in SIBO diagnostics. The currently used breath test has low sensitivity and specificity. Therefore, the additional validation studies are undergoing to define standard protocols. The growing technological developments in the field of medical devices have offered various innovative products to diagnose several complex human health conditions. Thus, to diagnose SIBO, an innovative orally ingested capsule technology is in the developmental process. It is designed in a way to measure in vivo hydrogen and carbon-di-oxide after ingestion of a carbohydrate meal and provide a technologically updated alternative to the current breath hydrogen test. It is expected that the capsule technology will help in diagnosing samples of small bowel bacteria. Thus, the introduction of capsule technology is likely to emerge in the coming future and contribute to direct and accurate evaluation of SIBO and offer vital growth opportunities for the North America market’s growth.
In terms of diagnosis, the breath testing segment accounted for the largest share of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020. In terms of type, the hydrogen-predominant SIBO segment held a larger market share of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020.
A few major primary and secondary sources referred to for preparing this report on the North America small intestinal bacterial overgrowth (SIBO) diagnostics market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Aerodiagnostics, LLC.; Commonwealth Diagnostics International; DirectLabs, LLC.; Genova Diagnostics; Health Associates Medical Group; Metabolic Solutions, Inc.; Pivotal Diagnostics; SIBO Diagnostics; SIBOTest; and Vibrant Wellness.
The North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market is valued at US$ 53,452.06 thousand in 2021, it is projected to reach US$ 73,794.03 thousand by 2028.
As per our report North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market, the market size is valued at US$ 53,452.06 thousand in 2021, projecting it to reach US$ 73,794.03 thousand by 2028. This translates to a CAGR of approximately 4.7% during the forecast period.
The North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report:
The North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market
